Cyclerion Therapeutics (CYCN) Competitors $3.45 +0.10 (+2.99%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCN vs. FGEN, INKT, BRNS, ALGS, GBIO, VYNE, DARE, CLNN, TPST, and GDTCShould you be buying Cyclerion Therapeutics stock or one of its competitors? The main competitors of Cyclerion Therapeutics include FibroGen (FGEN), MiNK Therapeutics (INKT), Barinthus Biotherapeutics (BRNS), Aligos Therapeutics (ALGS), Generation Bio (GBIO), VYNE Therapeutics (VYNE), Daré Bioscience (DARE), Clene (CLNN), Tempest Therapeutics (TPST), and CytoMed Therapeutics (GDTC). These companies are all part of the "pharmaceutical products" industry. Cyclerion Therapeutics vs. FibroGen MiNK Therapeutics Barinthus Biotherapeutics Aligos Therapeutics Generation Bio VYNE Therapeutics Daré Bioscience Clene Tempest Therapeutics CytoMed Therapeutics FibroGen (NASDAQ:FGEN) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations. Which has preferable valuation and earnings, FGEN or CYCN? Cyclerion Therapeutics has lower revenue, but higher earnings than FibroGen. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M1.15-$284.23M-$0.48-0.70Cyclerion Therapeutics$2M4.67-$5.26M-$1.22-2.83 Does the MarketBeat Community believe in FGEN or CYCN? FibroGen received 312 more outperform votes than Cyclerion Therapeutics when rated by MarketBeat users. Likewise, 59.04% of users gave FibroGen an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote. CompanyUnderperformOutperformFibroGenOutperform Votes34659.04% Underperform Votes24040.96% Cyclerion TherapeuticsOutperform Votes3458.62% Underperform Votes2441.38% Which has more risk & volatility, FGEN or CYCN? FibroGen has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Does the media favor FGEN or CYCN? In the previous week, FibroGen had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for FibroGen and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat FibroGen's score of 0.94 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment FibroGen Positive Cyclerion Therapeutics Very Positive Do analysts recommend FGEN or CYCN? FibroGen currently has a consensus price target of $10.00, suggesting a potential upside of 2,858.58%. Given FibroGen's stronger consensus rating and higher probable upside, research analysts plainly believe FibroGen is more favorable than Cyclerion Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Cyclerion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is FGEN or CYCN more profitable? Cyclerion Therapeutics has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-67.66% N/A -36.17% Cyclerion Therapeutics N/A -55.32%-48.35% Do institutionals and insiders believe in FGEN or CYCN? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 2.0% of FibroGen shares are held by company insiders. Comparatively, 36.1% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryFibroGen beats Cyclerion Therapeutics on 11 of the 18 factors compared between the two stocks. Get Cyclerion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCN vs. The Competition Export to ExcelMetricCyclerion TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.35M$6.89B$5.56B$7.83BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.837.4422.4818.48Price / Sales4.67242.70394.56103.59Price / CashN/A65.8538.1834.62Price / Book0.756.516.774.25Net Income-$5.26M$143.21M$3.22B$248.23M7 Day Performance14.62%1.98%1.48%0.89%1 Month Performance35.83%6.89%3.99%3.53%1 Year Performance20.63%-2.52%16.15%5.08% Cyclerion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCNCyclerion Therapeutics1.8431 of 5 stars$3.45+3.0%N/A+18.6%$9.35M$2M-2.8330Upcoming EarningsPositive NewsFGENFibroGen4.5852 of 5 stars$0.29+0.1%$10.00+3,388.0%-69.8%$28.93M$29.62M-0.23570Upcoming EarningsAnalyst ForecastINKTMiNK Therapeutics2.7551 of 5 stars$7.26+0.1%$37.50+416.5%-23.5%$28.79MN/A-1.8630Positive NewsBRNSBarinthus Biotherapeutics2.3488 of 5 stars$0.71-2.7%$5.17+627.7%-45.4%$28.64M$14.97M-0.48107Short Interest ↑Gap UpALGSAligos Therapeutics3.7633 of 5 stars$4.62-1.3%$70.00+1,415.2%-70.8%$28.25M$3.95M-0.3590Upcoming EarningsGap DownGBIOGeneration Bio3.5867 of 5 stars$0.42+6.4%$7.33+1,658.6%-84.7%$27.94M$19.89M-0.19150Positive NewsHigh Trading VolumeVYNEVYNE Therapeutics2.4742 of 5 stars$1.79-3.2%$6.88+284.1%-47.2%$27.23M$501,000.00-2.0830Upcoming EarningsShort Interest ↑DAREDaré Bioscience2.2926 of 5 stars$2.97+2.4%$24.00+708.1%-20.1%$26.28M$9,784.00-5.0330Short Interest ↓Positive NewsCLNNClene2.8313 of 5 stars$3.02+0.7%$55.25+1,729.5%-65.6%$25.96M$342,000.00-0.57100Upcoming EarningsTPSTTempest Therapeutics2.214 of 5 stars$7.11-2.3%$30.00+321.9%-84.2%$25.02MN/A-4.6520Upcoming EarningsGDTCCytoMed Therapeutics2.1512 of 5 stars$2.28-7.3%$5.00+119.3%+12.3%$24.94MN/A0.00N/AGap Down Related Companies and Tools Related Companies FGEN Competitors INKT Competitors BRNS Competitors ALGS Competitors GBIO Competitors VYNE Competitors DARE Competitors CLNN Competitors TPST Competitors GDTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCN) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclerion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclerion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CYCN Stock Free CYCN Stock Alerts